Csl Plasma, Inc

CLIA Laboratory Citation Details

4
Total Citations
14
Total Deficiencyies
10
Unique D-Tags
CMS Certification Number 11D2064762
Address 1283 Columbia Drive, Decatur, GA, 30032
City Decatur
State GA
Zip Code30032
Phone(404) 424-8503

Citation History (4 surveys)

Survey - January 21, 2021

Survey Type: Standard

Survey Event ID: 72LE11

Deficiency Tags: D0000 D5401 D6054

Summary:

Summary Statement of Deficiencies D0000 A Clinical Laboratory Improvement Amendments (CLIA) recertification survey was completed on January 22, 2021. The laboratory was not in compliance with applicable CLIA requirements found at 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on review of the policy and procedure manual (SOP) and staff interview, the laboratory failed to follow written policies and procedures as required. Findings include: 1. SOP review revealed the laboratory did not follow the established competency policy and procedure for four (4) of the twelve (12) moderate complexity testing personnel (TP) annual competencies performed in 2019. 2. An interview with the Assistant Quality Manager on 1/21/2021 in a conference room at approximately 11:30 a.m. confirmed the established annual TP competency policy and procedure was not followed for the evaluation of aforementioned TP in 2019.. D6054 TECHNICAL CONSULTANT RESPONSIBILITIES CFR(s): 493.1413(b)(9) The technical consultant is responsible for evaluating and documenting the performance of individuals responsible for moderate complexity testing at least annually, after the first year. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on testing personnel (TP) document review and staff interview, the technical consultant (TC) failed to perform and document annual competencies for moderate complexity TP after the first year as required. Findings include: 1. TP competency document review revealed 2019 annual competency documents were not available at the time of survey for the following TP (CMS 209 - page 1 of 2): TP #9, TP #11, and TP #12; for (CMS 209 - page 2 of 2): TP #9. 2. An interview with the Assistant Quality Manager in a conference room on 1/21/2021 at approximately 11:00 a.m. comfirmed the aforementioned lack of TP annual competency documents at the time of survey. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - December 13, 2018

Survey Type: Special

Survey Event ID: 9KQK11

Deficiency Tags: D0000 D2016 D2089 D2096 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 A proficiency testing desk review was completed on December 13, 2018. At the time of the review, the laboratory was not in compliance with the Clinical Laboratory Improvement Amendments of 1988, 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports, the laboratory failed to maintain satisfactory performance in three of five consecutive events (1 and 3rd events of 2017 and 2nd Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- event of 2018), resulting in the second unsuccessful occurrence for Routine Chemistry analyte # 245 including: Total Protein, analyte # 485. Findings include: Refer to D 2096 & D 2089 D2089 ROUTINE CHEMISTRY CFR(s): 493.841(c) Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3)The laboratory participated in the previous two proficiency testing events. This STANDARD is not met as evidenced by: Based on review of the laboratory's proficiency testing (PT) reports and an on-line chat with a representative from the laboratory's proficiency testing agency, the American Association of Bioanalysts (AAB), the laboratory failed to submit results for the 2nd event of 2018. This resulted in receiving scores of 0%, which resulted in the second unsuccessful occurrence for Routine Chemistry analyte # 245 including: Total Protein, analyte # 485. Findings include: 1. Desk review of the laboratory's proficiency testing reports from the American Association of Bioanalysts (AAB) revealed the laboratory received scores of 0% for Routine Chemistry and Total Protein on event 2 of 2018. 2. An On-line chat with a representative from AAB on November 7, 2018 at am 11:30 am confirmed the laboratory did not submit results for the 2nd event of 2018 so they received scores of 0%. This resulted in the second unsuccessful performance for Routine Chemistry, analyte #245 and Total Protein, analyte # 485. D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports, the laboratory failed to maintain satisfactory performance in three of five consecutive events (1st and 3rd events of 2017 and 2nd event of 2018), resulting in the second unsuccessful occurrence for Routine Chemistry analyte # 245 including: Total Protein, analyte # 485. Findings include: 1. Desk review of Casper Reports 153 and 155 disclosed the laboratory failed the speciality of Routine Chemistry, analyte # 245 and analyte #485 Total Protein on event 1 of 2017 with a score of 60%, event 3 of 2017 with a score of 40% and event 2 of 2018 with a score of 0% for non-participation. 2. Desk review of the laboratory's proficiency testing reports from the American Association of Bioanalysts (AAB)confirmed the -- 2 of 3 -- laboratory failed Routine Chemistry and Total Protein on Events 1 and 3 of 2017 and Event 2 of 2018 resulting in the second unsuccessful performance. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports, the laboratory director failed to ensure the laboratory maintained satisfactory performance in three of five consecutive events (1st and 3rd events of 2017 and 2nd event of 2018), resulting in the second unsuccessful occurrence for Routine Chemistry analyte # 245 including: Total Protein, analyte # 485. Findings include: Refer to D6016 D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports, the laboratory director failed to ensure the laboratory maintained satisfactory performance in three of five consecutive events (1st and 3rd events of 2017 and 2nd event of 2018), resulting in the second unsuccessful occurrence for Routine Chemistry analyte # 245 including: Total Protein, analyte # 485. Findings include: 1. Desk review of Casper Reports 153 and 155 disclosed the laboratory failed the speciality of Routine Chemistry, analyte # 245 and analyte #485 Total Protein on event 1 of 2017 with a sccore of 60%, event 3 of 2017 with a score of 40% and event 2 of 2018 with a score of 0% for non-participation. 2. Desk review of the laboratory's proficiency testing reports from the American Association of Bioanalysts (AAB)confirmed the laboratory failed Routine Chemistry and Total Protein on Events 1 and 3 of 2017 and Event 2 of 2018 resulting in the second unsuccessful performance. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 28, 2018

Survey Type: Standard

Survey Event ID: DVTJ11

Deficiency Tags: D0000 D6029

Summary:

Summary Statement of Deficiencies D0000 A Clinical Laboratory Improvement Amendments (CLIA) recertification survey was completed on September 28, 2018. The laboratory was not in compliance with applicable CLIA requirements found at 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D6029 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(11) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(11) Ensure that prior to testing patients' specimens, all personnel have the appropriate education and experience, receive the appropriate training for the type and complexity of the services offered, and have demonstrated that they can perform all testing operations reliably to provide and report accurate results. This STANDARD is not met as evidenced by: Based on staff document review and staff interview, the laboratory director (LD) failed to ensure all personnel have the appropriate training for the type and complexity of the services offered. Findings include: 1. Personnel document review revealed Staff #34 TC#1 (CMS 209) did not have an initial competency performed in 2018. 2. An interview with the center manager on 9/28/18 in a conference room at approximately 2:00 p.m. confirmed the initial competency was not available for the aforementioned staff at the time of survey. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 2, 2018

Survey Type: Special

Survey Event ID: TUK811

Deficiency Tags: D0000 D2016 D2097

Summary:

Summary Statement of Deficiencies D0000 A proficiency testing desk review was completed on January 2, 2018. At the time of the review, the laboratory was not in compliance with the Clinical Laboratory Improvement Amendments of 1988, 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports, the laboratory failed to maintain satisfactory performance in two of three consecutive events (1st event of 2017 and 3rd event of Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- 2017), resulting in the first unsuccessful occurrence for Routine Chemistry # 245 and analyte # 485 total protein. Findings include: Refer to D 2097 D2097 ROUTINE CHEMISTRY CFR(s): 493.841(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on proficiency testing desk review using the Centers for Medicare and Medicaid (CMS) Casper Reports 155 and 153 and review of the laboratory's proficiency testing (PT) reports from the American Association of Bioanalyst (AAB), the laboratory failed to maintain satisfactory performance in two of three consecutive events (1st event of 2017 and 3rd event of 2017), resulting in the first unsuccessful occurrence for Routine Chemistry # 245 and analyte # 485, total protein. Findings include: 1. Desk review of Casper Reports 153 and 155 disclosed the laboratory failed Routine Chemistry # 245 and analyte # 485,total protein, on event 1 of 2017 with a score of 60% and event 3 of 2017 with a score of 40%. 2. Desk review of the laboratory's proficiency testing reports from AAB confirmed the laboratory failed Routine Chemistry and total protein on event 1 of 2017 and event 3 of 2017 resulting in the first unsuccessful performance. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access